BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 36223209)

  • 1. Path of least recurrence: A systematic review and meta-analysis of fidaxomicin versus vancomycin for Clostridioides difficile infection.
    Liao JX; Appaneal HJ; Vicent ML; Vyas A; LaPlante KL
    Pharmacotherapy; 2022 Nov; 42(11):810-827. PubMed ID: 36223209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of antibiotic therapy for Clostridioides difficile infection on mortality and other patient-relevant outcomes: a systematic review and meta-analysis.
    Stabholz Y; Paul M
    Clin Microbiol Infect; 2024 Jan; 30(1):51-58. PubMed ID: 37690610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults.
    Nelson RL; Suda KJ; Evans CT
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD004610. PubMed ID: 28257555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Open-Label, Randomized Trial Comparing Fidaxomicin With Oral Vancomycin for the Treatment of Clostridioides difficile Infection in Hospitalized Patients Receiving Concomitant Antibiotics for Concurrent Infections.
    Rao K; Zhao Q; Bell J; Krishnan J; Henig O; Daniel J; Sawaya K; Albin O; Mills JP; Petty LA; Gregg K; Kaul D; Malani AN; Pogue J; Kaye KS
    Clin Infect Dis; 2024 Feb; 78(2):277-282. PubMed ID: 37797310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin.
    Cornely OA; Miller MA; Louie TJ; Crook DW; Gorbach SL
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S154-61. PubMed ID: 22752865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of fidaxomicin versus oral vancomycin in the treatment of recurrent clostridioides difficile.
    Rinaldi A; Reed EE; Stevenson KB; Coe K; Smith JM
    J Clin Pharm Ther; 2021 Aug; 46(4):993-998. PubMed ID: 33609052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan.
    Mikamo H; Tateda K; Yanagihara K; Kusachi S; Takesue Y; Miki T; Oizumi Y; Gamo K; Hashimoto A; Toyoshima J; Kato K
    J Infect Chemother; 2018 Sep; 24(9):744-752. PubMed ID: 29934056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral fidaxomicin versus vancomycin for the treatment of Clostridioides difficile infection: A systematic review and meta-analysis of randomized controlled trials.
    Tashiro S; Mihara T; Sasaki M; Shimamura C; Shimamura R; Suzuki S; Yoshikawa M; Hasegawa T; Enoki Y; Taguchi K; Matsumoto K; Ohge H; Suzuki H; Nakamura A; Mori N; Morinaga Y; Yamagishi Y; Yoshizawa S; Yanagihara K; Mikamo H; Kunishima H
    J Infect Chemother; 2022 Nov; 28(11):1536-1545. PubMed ID: 35964806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults.
    van Prehn J; Reigadas E; Vogelzang EH; Bouza E; Hristea A; Guery B; Krutova M; Norén T; Allerberger F; Coia JE; Goorhuis A; van Rossen TM; Ooijevaar RE; Burns K; Scharvik Olesen BR; Tschudin-Sutter S; Wilcox MH; Vehreschild MJGT; Fitzpatrick F; Kuijper EJ;
    Clin Microbiol Infect; 2021 Dec; 27 Suppl 2():S1-S21. PubMed ID: 34678515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials.
    Crook DW; Walker AS; Kean Y; Weiss K; Cornely OA; Miller MA; Esposito R; Louie TJ; Stoesser NE; Young BC; Angus BJ; Gorbach SL; Peto TE;
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S93-103. PubMed ID: 22752871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microbiome-preserving antibiotics for the treatment of Clostridioides difficile infection: a systematic review and meta-analysis.
    Kravets AM; Hanneke R; Nelson RL
    Tech Coloproctol; 2023 Dec; 28(1):20. PubMed ID: 38112980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.
    Louie TJ; Cannon K; Byrne B; Emery J; Ward L; Eyben M; Krulicki W
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S132-42. PubMed ID: 22752862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in Japan.
    Okumura H; Ueyama M; Shoji S; English M
    J Infect Chemother; 2020 Jun; 26(6):611-618. PubMed ID: 32165072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection.
    Nathwani D; Cornely OA; Van Engen AK; Odufowora-Sita O; Retsa P; Odeyemi IA
    J Antimicrob Chemother; 2014 Nov; 69(11):2901-12. PubMed ID: 25096079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study.
    Polivkova S; Krutova M; Capek V; Sykorova B; Benes J
    Int J Infect Dis; 2021 Feb; 103():226-233. PubMed ID: 33188906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Fidaxomicin and Vancomycin in Children and Adolescents with Clostridioides (Clostridium) difficile Infection: A Phase 3, Multicenter, Randomized, Single-blind Clinical Trial (SUNSHINE).
    Wolf J; Kalocsai K; Fortuny C; Lazar S; Bosis S; Korczowski B; Petit A; Bradford D; Croos-Dabrera R; Incera E; Melis J; van Maanen R
    Clin Infect Dis; 2020 Dec; 71(10):2581-2588. PubMed ID: 31773143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Systematic Literature Review of Economic Evaluations of Antibiotic Treatments for Clostridium difficile Infection.
    Burton HE; Mitchell SA; Watt M
    Pharmacoeconomics; 2017 Nov; 35(11):1123-1140. PubMed ID: 28875314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fidaxomicin compared with vancomycin and metronidazole for the treatment of Clostridioides (Clostridium) difficile infection: A network meta-analysis.
    Okumura H; Fukushima A; Taieb V; Shoji S; English M
    J Infect Chemother; 2020 Jan; 26(1):43-50. PubMed ID: 31624029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world comparison of fidaxomicin versus vancomycin or metronidazole in the treatment of Clostridium difficile infection: a systematic review and meta-analysis.
    Dai J; Gong J; Guo R
    Eur J Clin Pharmacol; 2022 Nov; 78(11):1727-1737. PubMed ID: 36057672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective, observational study of fidaxomicin use for
    Guery B; Berger P; Gauzit R; Gourdon M; Barbut F; ; Dafne Study Group ; Bémer P; Bessède E; Camou F; Cattoir V; Couzigou C; Descamps D; Dinh A; Laurans C; Lavigne JP; Lechiche C; Leflon-Guibout V; Le Monnier A; Levast M; Mootien JY; N'Guyen Y; Piroth L; Prazuck T; Rogeaux O; Roux AL; Vachée A; Vernet Garnier V; Wallet F
    J Int Med Res; 2021 Jun; 49(6):3000605211021278. PubMed ID: 34162264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.